Refining Adjuvant Treatment IN Endometrial Cancer Based On Molecular Features: the p53abn-RED Trial, the MMRd-GREEN Trial, the NSMP-ORANGE Trial and the POLEmut-BLUE Trial
The RAINBO umbrella program consists of four clinical trials investigating new adjuvant therapies in endometrial cancer patients. Eligible patients will be assigned to one of the four RAINBO trials based on the molecular profile of their cancer:
p53 abnormal endometrial cancer patients to the p53abn-RED trial
mismatch repair deficient endometrial cancer patients to the MMRd-GREEN trial
no specific molecular profile endometrial cancer patients to NSMP-ORANGE trial
POLE mutant endometrial cancer patients to the POLEmut-BLUE trial
100 Clinical Results associated with Institute Gustave Rousse
0 Patents (Medical) associated with Institute Gustave Rousse
100 Deals associated with Institute Gustave Rousse
100 Translational Medicine associated with Institute Gustave Rousse